http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Stoss, O (검색결과 1 건)
- 무료
- 기관 내 무료
- 유료
-
Assessment of a HER2 scoring system for gastric cancer: results from a validation study
Hofmann, M,Stoss, O,Shi, D,Bü,ttner, R,van de Vijver, M,Kim, W,Ochiai, A,Rü,schoff, J,Henkel, T Blackwell Publishing Ltd 2008 Histopathology Vol.52 No.7
<P>Aims: </P><P>Human epidermal growth factor receptor 2 (HER2) overexpression/amplification is implicated in the development of various solid tumour types. Validated methods and scoring systems for evaluating HER2 status exist in breast cancer, but not in gastric cancer. The aim was to establish a HER2 scoring system for gastric cancer to identify suitable patients for enrolment in a trial of trastuzumab (Herceptin<SUP>®</SUP>) in advanced metastatic gastric cancer.</P><P>Methods and results: </P><P>Formalin-fixed paraffin-embedded gastric cancer samples were tested for HER2 status using the fluorescence <I>in situ</I> hybridization (FISH) pharmDx™ kit (Dako Denmark A/S). Immunohistochemistry (IHC) was performed using the HercepTest™ (Dako). Concordance between FISH and IHC was 93.5% in 168 evaluable samples. Eleven samples were scored as FISH+ but IHC− or equivocal.</P><P>Conclusions: </P><P>IHC/FISH discrepancies were attributed to basolateral membranous immunoreactivity of glandular cells resulting in incomplete membranous reactivity and/or a higher rate of tumour heterogeneity in gastric cancer compared with breast cancer. With modifications to the IHC scoring system, the HercepTest™ is considered valid for the identification of HER2+ gastric tumours for this clinical trial. Correlation of HER2 scores with clinical outcomes will be needed to determine which patients might benefit from trastuzumab therapy.</P>
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
